LEO Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LEO Pharma A/S
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
Operating “at the intersection of medicine and entertainment,” Level Ex is partnering with medical device companies to create specific video gaming content to train surgeons on new products, and creating sponsored content for free for physicians.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- LEO Pharma Inc.
- Peplin, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.